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368a CELL PROCESSING -  EX VIVO EXPANSION AND HEMATOPOIETIC MICROENVIRONMENT
1638 457-III
Large ex vivo expansion and reduced all orea ctivity of umbilical cord b lood  T  
lymphocytes. D. Skea, N. Chang, B. Dabek, R. Hedge and D. Bell. X-Cell Biotech 
Division, Hemos al Inc., Etobicoke, ON, Canada.
The use of human umbilical cord blood as a source of transplantable 
hematopoietic stem cells and progenitor cells may present some advantages over the 
use of bone marrow. For example, it has been suggested that the degree o f  HLA~ 
matching may be less stringent and the risk of graft-vs.-host disease (GvHD) may be 
lower. We have been studying the ex vivo expansion of umbilical cord blood T 
lymphocytes with a view to their use in the adoptive immunotherapy of cancer, 
autoimmunity and infectious disease. We have developed a new method, involving 
the use of a conditioned medium (XLCM™), that consistently results in levels of 
umbilical cord blood T cell expansion not hitherto possible. Primary cultures of 
unfractionated low density mononuclear cells (LDMNC) derived from umbilical 
cord blood treated with 5% XLCM™ routinely show expansions greater than 
10,000-fold within a time period of four weeks. By contrast, similar FBS-free 
cultures treated with IL-2 expand less than 10-fold and not beyond one week, while 
cultures treated with IL-2 and concanavalin A expand to a maximum of only 300- 
500-fold over two weeks and again, fail to continue to proliferate thereafter. The 
monoclonal antibody, OKT3, which, when combined with IL-2 and FBS, is known 
to stimulate proliferation of adult peripheral blood lymphocytes, permitted only a 
17-fold expansion of umbilical cord blood lymphocytes under the same conditions. 
Thus, XLCM™, which also stimulates adult peripheral blood lymphocyte expansion 
to levels exceeding 100,000-fold in three to four weeks, is uniquely able to stimulate 
proliferation of umbilical cord blood lymphocytes to high levels. Cultures of 
XLCM™-stimulated umbilical cord or adult peripheral blood LDMNC are 
dominated by CD4+ T  lymphocytes for approximately the first two weeks. By four 
weeks, greater than 80% of the cultured cells bear the CD8+ phenotype. By contrast, 
umbilical cord blood T  lymphocytes cultured in the presence of IL-2 are all 
predominantly CDS+. Thus XLCM™ not only promotes high levels of umbilical cord 
blood T lymphocyte expansion not previously possible, but it also permits the 
selective expansion of different T lymphocyte subsets from a single source, 
Furthermore, we have shown that umbilical cord blood lymphocytes are both weaker 
stimulators and poorer responders compared to adult peripheral blood lymphocytes 
in  allogeneic mixed leukocyte reactions. These results suggest that adoptive 
immunotherapy with umbilical cord blood lymphocytes may be associated with less 
risk  of GvHD. The selective and extensive expansion of subsets of the less 
iilloreactive umbilical cord blood derived T lymphocytes could be extremely useful 
in  the development of adoptive immunotherapies focusing on specific functional T 
lymphocytes subsets.
1639 458-m
R e p o r t  on the 's tandard iza tion  of clonogeneic hematopoietic precursor assays 
f o r  the unrelated donor bone m arrow  transplantation trial. C.A. Keever-Taylor, 
N.H. Collins, S. Carter, L. Kelley, A. Gee and S. Fuller, For the National Heart, 
L ung  & Blood Insti tute, Unrelated Donor Bone Marrow Transplantation Trial 
Laboratory Committee; Medical College o f  Wisconsin, Milwaukee, WI.
It has been previously recognized that clonongeneic assays for committed 
progenitors are poorly reproducible between laboratories. This has largely been 
ascribed to the use of locally prepared materials and reagents and to differences in 
criteria for colony scoring. The Laboratory Committee for the Unrelated Donor Trial 
w a s  charged to standardize this assay for the monitoring of progenitor cell content in 
infused marrow. To this end a written protocol was developed requiring a 
commercially available reagent kit utilizing recombinant cytokines to stimulate 
co lony growth. This was supplemented with training sessions, an illustrated manual 
f o r  scoring and a series of cell exchanges with follow-up conference calls to discuss 
results. A total of 12-14 labs participated in 4 separate cell exchanges in which 2 
sam ples of marrow were tested at 2 plating concentrations for BFU-e and CFU-GM 
content. The source laboratory prepared and shipped identical marrow samples via 
overn ight carrier. All exchanges included nonmanipulated marrow. The first 3 
exchanges included marrow T cell depleted (TCD) by counterflow centrifugal 
élutriation and the 4th exchange included marrow TCD by complement-mediated 
ly s i s  with a T-cell specific moAb, Exchange #1 required on site preparation of 
mononuclear cells from the unmanipulated marrow, while subsequent exchanges 
u s e d  whole marrow. Plating concentrations included 2.5 x Í04/mLin all exchanges, 5 
x  lOVmL in Exchange #1 and 1 x lOVmL in Exchanges 2-4. One mL cultures were 
p la ted  in triplicate in 35 mm culture plates. Incubation was at 37°C for 14 days in a 
well-humidified atmosphere of 5% C 0 2, Colonies per 10* cells were calculated for 
e a c h  plate in which the total colonies did not exceed 100. Viability was >85% for all 
shipped samples with the exception of the sample TCD by mo Ab that had to be 
dropped from analysis due to poor viability. There was considerable variability 
w ithin  a lab, as determined by assessment of the coefficient of variation between the 
tw o  plating concentrations and among the replicate cultures. Variation between labs 
w a s  even higher as assessed from data expressed as the average of both 
concentrations to the 105 cells plated. The coefficient of variation for the 4 
exchanges ranged from 29.4% to 86% and did not improve over time. There was 
greater variation in samples with the lowest colony growth. Eleven of the 14 
participating labs reported data >1 SD from the mean on one or more occasions. 
Variability was similar for CFU-GM and BFU-e. We conclude that variability in the 
C F U  assay is not due solely to differences in methodology or scoring criteria, but 
m ay  additionally be affected by shipping, conditions of incubation or technical skill. 
Alternative methods for measuring stem cell content that are more amendable to
standardization, (e.g., Assessment of CD34 content), may be a preferred measure of 
stem cell content.
1640 459-m
No expression of LFA-1 on m urine hematopoietic p rogenitor cells with colony- 
forming or radioprotective capacity. J.F.M. Pruijt, C.G. Figdor, Y. van Kooyk, R. 
Willemze and W.E. Fibbe. Laboratory o f  Experimental Hematology, Leiden 
University Medical Center and Laboratory' o f  Tumor Immunology, University 
Hospital Nijmegen, The Netherlands.
The ß3-integrin LFA-1 (C D Tlla) is expressed in-vitro on human committed 
hematopoietic progenitor cells (HPC) (Blood 80: 429, 1992 and 87: 4120, 1996), 
Recently, we have demonstrated that anti-LFA-1 blocking antibodies completely 
prevent the rapid mobilization of HPC with colony-forming and radioprotective 
capacity induced by IL-8 in mice (Blood 86: 1886a, 1996 (Abstr.)). We therefore, 
studied the expression and functional role of LFA-1 on HPC in-vitro and in-vivo. 
First, bone marrow (BM)-derived mononuclear cells (MNC) from BALB/c mice 
were incubated with anti-LFA-1 antibody (H I54.163) and Goat-anti-Rat-Pe 
(GaRa-Pe). In the B M ±50%  of the MNC were LFA-1 "P*\ Cultures supplemented 
with G(M)-CSF/IL-l/IL-3/IL~6/SCF and EPO of 7500 sorted cells indicated that the 
L F A -1 fra c t io n  contained the majority of the colony forming cells (CFU) (LFA-lKi 
154 ± 64  v. L F A -l^  22 ±13 , m ean±SD , n = 5). To assess the radioprotective 
capacity, lethally-irradiated recipient mice were transplanted with increasing 
numbers of BM-derived LFA-l'1'1 or LFA-l1"“ MNC. The radioprotective capacity 
resided almost entirely in the LFA-1W# cell fraction, the radioprotection rate after 
transplantation of 10\ 3 x 103, 104 and 3 x IO4 cells being 80, 80, 100 and 100% 
respectively. In contrast, after transplantation of 3 x 10\ 104 and 3 x 104 LFA-1 ^  
cells, a radioprotection rate of I I ,  0 and 30% was obtained. Subsequently, BM- 
derived sorted Wheat-germ-agglutinin (WGA)l"7Lin"fi cells were stained with 
rhodamine (Rho) (100 ng/ml, 20'37°C), followed by incubation in Rho free medium 
(20'37°C). Rho1** cells were isolated and incubated with anti-LFA-1 antibody and 
GaRa-Pe,
> 95% of the Rho"** cells were LFA -lm“. Cultures of 750 sorted cells showed that 
the LFA-1 fraction contained all CFU (247 v. 1, mean, n = 4). Transplantation of 
150 Rho"*" LFA-l"^ or up to 600 Rho'";u LFA-1|KM cells protected 100 and 0% of 
lethally-irradiated recipient mice, respectively. These results show that HPC with 
colony-forming or radioprotective capacity in steady-state BM do not express LFA-1.
1641 460-111
Expression of APO-l/FAS antigen (CD95) in peripheral blood progenitor cells 
(PBPC) is influenced by the mobilisation regimen used. A.C, Parker, J.I.O. Craig 
and R,S. Anthony. University o f  Edinburgh, John Hughes Bennett Laboratory, 
Western General Hospital, Edinburgh, Scotland, UK,
Fas antigen (CD95) is a trans membrane protein belonging to the TNF 
superfamily. Activation by its ligand results in cell death through apoptosis. Fas is 
expressed at low levels on unstimulated CD34+ bone marrow (BM) cells but 
increases following exposure to growth factors including G-CSF, The majority of 
PBPC are mobilised with a combination of chemotherapy + G-CSF. The effects of 
mobilisation on Fas expression are unknown. Using dual colour flow cytometry, Fas 
expression was studied on CD34 + ve progenitor cells from PBPC harvests collected 
after mobilisation with either cyclophosphamide (Cy) + G-CSF (300 ^ig/kg/day for 8 
days) or standard chemotherapy + G-CSF. Thirty nine PBPC harvests from patients 
with acute leukaemia, CML, lymphoma and 5 normal bone marrows were analysed. 
The CD95 FITC fluorescence channel on the cytometer was calibrated with 
commercial microbeads to quantify Fas antigen expression as molecules/cell, A 
minor population of CD34+ cells in PBPC (22.3%) and BM (23.2%) were Fas+. 
There was no evidence for a higher percentage of CD34+ cells expressing Fas antigen 
in PBPC mobilised with G-CSF. However, there was a significant increase 
(p =  0.0003) in the receptor density when the number of molecules on the cell 
surface were analysed. The cell surface density of Fas increased from 2.2 x 10* 
molecules/cell in BM to 6,2 x 10* molecules/cell in PBPC. Mobilisation with Cy 
increased the average yield of CD34+ progenitor cells from 2.47 x 107kg with 
standard chemotherapy to 4.48 x lO'Vkg, The use of Cy significantly decreased the 
number of CD34+ cells that were Fas+ (Cy 15,0%, standard chemotherapy 42.4%; 
p =s 0.0018) and the density of Fas molecule expression on progenitor cells (Cy 4.5 x 
1( f  molecules/cell, standard chemotherapy 11.1 x 10* molecules/cell; p = 0.039). In 
conclusion, the type of cytotoxic drug used for mobilisation appears to influence the 
level of Fas expression in PBPC. The use of haematopoietic growth factor for 
mobilisation does not increase Fas expression in PBPC when compared to 
unstimulated BM progenitor cells. As there is differential expression of Fas during 
haematopoietic cell maturation, the lower levels of Fas expression found on Cy 
mobilised PBPC may indicate the presence of a more primitive progenitor cell 
population in these harvests.
1642 461-in
Phenotypic and functional analysis of CD34+ L-selectin subsets from human 
bone marrow, mobilized peripheral blood and umbilical cord blood. B. Bielorai, 
I. Kashiwakura, D. Sotiropoulos, G. Debnath, P.J. Hendrikx and J.W.M. Visser. 
Linds ley F, Kimbal Research Institute, New York Blood Center, New York, NY,
Interactions between hematopoietic stem cells (HSC) and the bone marrow (BM) 
microenvironment involve various adhesion molecules. L-selectin is one of the 
adhesion molecules expressed on HSC. Recent studies of clinical stem cell 
transplantation indicated that the number of CD34+ cells in mobilized peripheral
